Clinical value of combined detection of serum ProGRP, CEA, CYFRA211, NSE, CA199 and AFP in diagnosis of lung cancer

doi:10.3877/cma.j.issn.2095-5820.2019.02.004

Abstract

Abstract:

Objective

To explore the value of serum tumor markers ProGRP, carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA211), neuron specific enolase (NSE), carbohydrate antigen 199 (CA199) and alpha fetoprotein (AFP) in diagnosis of lung cancer.

Methods

Serum samples from 560 patients were collected in Third People′s Hospital of Kunming City during October 2016 to September 2017. Among them, 280 cases were lung cancer, 180 cases were benign lung disease and 100 cases were routine physical examination. The six tumor markers mentioned above in serum were detected by electrochemiluminescence immunoassay.

Results

The levels of ProGRP, CYFRA211, NSE, CEA and CA199 in lung cancer group were significantly higher than those in benign lung disease group and normal control group (χ²=401.251, 25.475, 35.292, 37.491 and 13.472, P<0.01, respectively). The serum levels of ProGRP, CYFRA211, NSE and CEA in small cell lung cancer group, adenocarcinoma group and squamous cell cancer group were significantly different (χ²=365.073, 15.657, 37.971 and 13.437, P<0.01, respectively). The sensitivity of combined detection of ProGRP and NSE in small cell lung cancer is 97.9%. The sensitivity of combined detection of CEA, CYFRA211 and NSE in adenocarcinoma was 87.7%.

Conclusion

The combined detection of serum tumor markers ProGRP, CEA, CYFRA211, NSE, CA199 and AFP has high clinical value for the diagnosis and monitoring of the curative effect of lung cancer. Combined detection of these markers can further improve the sensitivity and specificity.

Key words: Tumor markers, Lung cancer, Clinical value

Dongling Li, Shoufang Liu, Guangfeng Ying, Xiaofei Li, Songpeng Li. Clinical value of combined detection of serum ProGRP, CEA, CYFRA211, NSE, CA199 and AFP in diagnosis of lung cancer[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2019, 07(03): 145-149.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2019.02.004

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2019/V07/I03/145

Figures/Tables 6

References 19

1	Gao H, Liu J, Song N. Application of target peptide in siRNA delivery for the research of lung cancer therapy[J]. Chin J Lung Cancer, 2014,17(9):674-678.
2	么鸿雁，施侣元. 中国人群肺癌发病危险因素的Meta分析[J]. 中华流行病学杂志, 2003,24(1):45-49.
3	王磊，何洁，姚勇，等. 血清肿瘤标志物联合检测对肺癌的诊断价值[J]. 标记免疫分析与临床, 2013,26(3):2316-2317.
4	万程彬. 研究血清多种肿瘤标志物联合检测在肺癌诊断中的价值[J]. 中国医学创新, 2014,11(36):60-61.
5	李德经，宁国兰，柳兆飞，等. ProGRP和NSE对小细胞肺癌的诊断及疗效评估的价值[J]. 实用医学杂志, 2016,37(5):754-758.
6	倪军，郭子健，张力. 单独与联合检测四项肺癌血清肿瘤标志物在肺癌诊断中的价值[J]. 中华内科杂志, 2016,55(1):25-30.
7	姜晓明，陈爽，杜晓艳，等. 5种血清肿瘤标志物检测在肺癌诊断中的临床价值[J]. 吉林医药学院学报, 2013,34(2):81-84.
8	赵车东，闫玉珠，吴文婧，等. 血清CEA, CYFRA21-1和NSE水平在肺癌诊断与分型中的应用价值[J]. 现代检验医学杂志, 2016,31(6):59-61.
9	施城东，樊卫. 血清肿瘤标志物联合检测在肺癌患者中的诊断价值[J]. 国际检验医学杂志, 2016,37(10):1419-1421.
10	解宝泉，张志艳，王袁，等. 血清CEA、CYFRA21-1及SCCA检测对肺癌患者预后的评估价值[J]. 山东医药, 2017,57(7):54-56.
11	纪波，王启飞，穆玉恕，等. 肿瘤标志物联合检测在肺癌辅助诊断中的应用价值[J]. 实用临床医药杂志, 2013,17(17):32-35.
12	王春淑，李祥周. 产生AFP的肺癌4例报告[J]. 实用癌症杂志, 1999,14(1):65-67.
13	Wang J, Shi G, Zhang S, et al. Clinical value of serum TPS, CEA, ProGRP and CYFRA211 in patients with lung cancer[J]. Chin J Lung Cancer, 2010,13(5):500-505.
14	Zhao D, Cheng JI, Chen Y. Value of detecting serum tumor markers in diagnosis of lung cancer[J]. Jiangsu Med J, 2010,36(6):651-653.
15	Miyake Y, Kodama T, Yamaguchi K. Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma[J]. Cancer Res, 1994,54(8):2136-2140.
16	Tiseo M, Ardizzoni A, Cafferata MA, et al. Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer[J]. Anticancer Res, 2008,28(1B):507-513.
17	Ono A, Naito T, Ito I, et al. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer[J]. Lung Cancer, 2012,76(3):439-444.
18	王磊，何洁，姚勇，等. 血清肿瘤标志物联合检测对肺癌的诊断价值[J]. 标记免疫分析与临床, 2013,20(3):140-142.
19	纪波，王启飞，穆玉恕，等. 肿瘤标志物联合检测在肺癌辅助诊断中的应用价值[J]. 实用临床医药杂志, 2013,17(17):32-35.

组别	例数(例)	ProGRP (pg/ml)	CYFRA211 (ng/ml)	NSE (ng/ml)	CEA (ng/ml)	CA199 (U/ml)	AFP (ng/ml)
肺癌组	280	1197.24(1214.75)	10.48(24.89)	58.65(77.58)	65.34(198.63)	16.89(22.76)	5.23(2.81)
正常对照组	100	35.82(8.95)	2.07(1.56)	12.43(2.64)	2.56(1.48)	7.46(6.34)	4.97(2.67)
肺部良性疾病组	180	37.66(9.71)	2.35(1.72)	13.74(3.17)	3.45(3.41)	9.49(12.95)	4.62(2.06)

组别	例数(例)	ProGRP (pg/ml)	CYFRA211 (ng/ml)	NSE (ng/ml)	CEA (ng/ml)	CA199 (U/ml)	AFP (ng/ml)
肺癌组	280	1197.24(1214.75)	10.48(24.89)	58.65(77.58)	65.34(198.63)	16.89(22.76)	5.23(2.81)
正常对照组	100	35.82(8.95)	2.07(1.56)	12.43(2.64)	2.56(1.48)	7.46(6.34)	4.97(2.67)
肺部良性疾病组	180	37.66(9.71)	2.35(1.72)	13.74(3.17)	3.45(3.41)	9.49(12.95)	4.62(2.06)

组别	例数(例)	ProGRP(pg/ml)	CYFRA211(ng/ml)	NSE(ng/ml)	CEA(ng/ml)	CA199(U/ml)	AFP(ng/ml)
小细胞肺癌组	52	685.48(2739.42)	3.67(3.88)	40.91(70.82)	4.73(5.42)	13.75(16.68)	4.72(3.17)
腺癌组	112	69.77(38.62)	4.85(5.78)	16.23(9.54)	9.56(87.48)	15.33(40.12)	5.02(2.10)
鳞癌组	87	70.48(39.42)	8.46(17.25)	15.97(10.72)	3.45(4.40)	12.19(12.47)	4.89(2.86)

组别	例数(例)	ProGRP(pg/ml)	CYFRA211(ng/ml)	NSE(ng/ml)	CEA(ng/ml)	CA199(U/ml)	AFP(ng/ml)
小细胞肺癌组	52	685.48(2739.42)	3.67(3.88)	40.91(70.82)	4.73(5.42)	13.75(16.68)	4.72(3.17)
腺癌组	112	69.77(38.62)	4.85(5.78)	16.23(9.54)	9.56(87.48)	15.33(40.12)	5.02(2.10)
鳞癌组	87	70.48(39.42)	8.46(17.25)	15.97(10.72)	3.45(4.40)	12.19(12.47)	4.89(2.86)

肿瘤标志物	ROC曲线下的面积	95%置信区间
ProGRP	0.778	0.712~0.843
CYFRA211	0.838	0.787~0.944
NSE	0.891	0.847~0.940
CEA	0.843	0.779~0.901
CA199	0.423	0.354~0.531
AFP	0.223	0.201~0.305
CEA＋NSE	0.945	0.924~0.967
CEA＋CYFRA211	0.973	0.956~0.993
CEA＋CYFRA211＋NSE	0.984	0.972~1.000

Please choose a citation manager

Content to export